

4


Docket No. UF-293
Serial No. 10/036,988Remarks

A Notice of Allowance dated September 14, 2004 has been received, but the issue fee has not, as yet, been paid. Claims 1, 4, 5, and 7-10 have been allowed in the subject application. By this Amendment, the applicant has amended the claims to correct various omissions and typographical errors introduced into the claims in the Examiner's Amendment that accompanied the Notice of Allowance. These errors were also noted in the applicant's Statement of Substance of Interview under 37 C.F.R. §1.133, which was submitted to the Patent Office on September 24, 2004. For example, it was intended that recitation of the "compound" be replaced with "3-[2,4-dimethoxybenzylidene]-anabaseine (GTS-21), or pharmaceutically acceptable salt thereof" throughout the dependent claims, consistent with the Examiner's amendment to claim 1.

The applicant respectfully submits that these amendments will require no further search or examination on the part of the Examiner and do not constitute new matter. The amendments merely lend further clarity and consistency to the claims, and require no substantial amount of additional work on the part of the Patent Office. The applicant respectfully requests that the Examiner enter and make of record in the subject application the amendments presented herein.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

JAUF293\Amend-Kesp\312\Amend.doc\DNB/mv